395 related articles for article (PubMed ID: 27925203)
21. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
22. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network
Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
[TBL] [Abstract][Full Text] [Related]
24. The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Marchiò C; Dell'Orto P; Annaratone L; Geyer FC; Venesio T; Berrino E; Verdun di Cantogno L; Garofoli A; Rangel N; Casorzo L; dell'Aglio C; Gugliotta P; Trisolini E; Beano A; Pietribiasi F; Orlassino R; Cassoni P; Pich A; Montemurro F; Mottolese M; Vincent-Salomon A; Penault-Llorca F; Medico E; Ng CKY; Viale G; Sapino A
Am J Surg Pathol; 2018 Sep; 42(9):1190-1200. PubMed ID: 29975246
[TBL] [Abstract][Full Text] [Related]
25. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Lavigne M; Menet E; Tille JC; Lae M; Fuhrmann L; Bonneau C; Deniziaut G; Melaabi S; Ng CCK; Marchiò C; Rouzier R; Bièche I; Vincent-Salomon A
Mod Pathol; 2018 Jan; 31(1):68-82. PubMed ID: 28884749
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
Natrajan R; Wilkerson PM; Marchiò C; Piscuoglio S; Ng CK; Wai P; Lambros MB; Samartzis EP; Dedes KJ; Frankum J; Bajrami I; Kopec A; Mackay A; A'hern R; Fenwick K; Kozarewa I; Hakas J; Mitsopoulos C; Hardisson D; Lord CJ; Kumar-Sinha C; Ashworth A; Weigelt B; Sapino A; Chinnaiyan AM; Maher CA; Reis-Filho JS
J Pathol; 2014 Apr; 232(5):553-65. PubMed ID: 24395524
[TBL] [Abstract][Full Text] [Related]
29. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
[TBL] [Abstract][Full Text] [Related]
30. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
32. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
[No Abstract] [Full Text] [Related]
33. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
[TBL] [Abstract][Full Text] [Related]
34. Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Duprez R; Wilkerson PM; Lacroix-Triki M; Lambros MB; MacKay A; A'Hern R; Gauthier A; Pawar V; Colombo PE; Daley F; Natrajan R; Ward E; MacGrogan G; Arbion F; Michenet P; Weigelt B; Vincent-Salomon A; Reis-Filho JS
J Pathol; 2012 Feb; 226(3):427-441. PubMed ID: 22025283
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
36. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
37. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
38. Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity.
Soong TR; Dillon DA; Rice-Stitt TL; Wieczorek TJ; Baker GM; Darvishian F; Collins LC; Lester SC; Schnitt SJ; Harrison BT
Mod Pathol; 2022 Oct; 35(10):1370-1382. PubMed ID: 35477749
[TBL] [Abstract][Full Text] [Related]
39. Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma.
Wachter DL; Hartmann A; Beckmann MW; Fasching PA; Hein A; Bayer CM; Agaimy A
Biomed Res Int; 2014; 2014():408459. PubMed ID: 24701575
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems.
Righi L; Sapino A; Marchiò C; Papotti M; Bussolati G
Semin Diagn Pathol; 2010 Feb; 27(1):69-76. PubMed ID: 20306832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
